[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-blood-filter-treatment-that-lowers-blood-pressure-in-early-preeclampsia-how-a-novel-trial-could-extend-pregnancy-en":3,"ArticleBody_plCtovgxSNlHCFz1qEAa0xy0WCNMVP1M3ipG9wzmxA":197},{"article":4,"relatedArticles":168,"locale":54},{"id":5,"title":6,"slug":7,"content":8,"htmlContent":9,"excerpt":10,"category":11,"tags":12,"metaDescription":10,"wordCount":13,"readingTime":14,"publishedAt":15,"sources":16,"sourceCoverage":46,"transparency":48,"seo":51,"language":54,"featuredImage":55,"featuredImageCredit":56,"isFreeGeneration":60,"trendSlug":61,"niche":62,"geoTakeaways":66,"geoFaq":75,"entities":85},"69f160b33a60b2a09f4b96f6","Blood-Filter Treatment That Lowers Blood Pressure in Early Preeclampsia: How a Novel Trial Could Extend Pregnancy","blood-filter-treatment-that-lowers-blood-pressure-in-early-preeclampsia-how-a-novel-trial-could-extend-pregnancy","## Understanding Preeclampsia and the Need for Better Treatments\n\nPreeclampsia is a pregnancy‑specific disorder marked by new‑onset high blood pressure and organ dysfunction after 20 weeks of gestation in someone previously normotensive.[6] It is a leading hypertensive complication of pregnancy and a major global cause of maternal and fetal illness and death.[6]\n\n- Affects ~3–8% of pregnancies worldwide[3][6]  \n- Linked to >50,000 maternal and 500,000 fetal deaths annually[3][6]  \n\n**Key point:** Preeclampsia is common, dangerous, and the only curative therapy remains delivery.[6]\n\nMain risk factors include:\n\n- Previous preeclampsia  \n- Chronic kidney disease  \n- Diabetes  \n- Obesity  \n- Advanced maternal age[6]  \n\nThese guide closer surveillance and prevention but cannot reliably stop severe disease.[6]\n\nCurrent standard care focuses on:[6]\n\n- Controlling blood pressure with antihypertensives  \n- Monitoring kidney, liver, and neurological function  \n- Tracking fetal growth and placental health  \n- Planning safest timing and mode of delivery  \n\nBecause the placenta is central to the disease, removing it by delivery—induction or cesarean—is the only definitive cure.[6]\n\nThe greatest challenge is **severe early preeclampsia** (before 34 weeks), when clinicians must balance:\n\n- Maternal safety and risk of organ failure  \n- Harm from very preterm birth, where every added day in utero can improve neonatal outcome[4]  \n\nEven a short, safe prolongation of pregnancy can be clinically meaningful.[4]\n\n**Key takeaway:** Early severe preeclampsia forces a trade‑off between maternal protection and extreme prematurity, creating a window where innovative therapies could have major impact.[4][6]\n\n---\n\n## How the Blood-Filter Treatment Works and What the Trial Showed\n\nA key driver of preeclampsia appears to be soluble Flt‑1 (sFlt‑1), a placental protein that can reach about five times normal levels.[3]\n\nExcess sFlt‑1:[3]\n\n- Damages blood vessel function  \n- Promotes hypertension  \n- Causes kidney injury and proteinuria  \n- Contributes to liver and brain complications and poor fetal growth  \n\nTo target this, researchers:\n\n- Engineered an antibody that selectively binds sFlt‑1[4]  \n- Embedded it in an extracorporeal blood‑filtering device that removes sFlt‑1 while sparing other blood components—similar in concept to [dialysis](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FKidney_dialysis)[4]  \n\nThe device underwent animal and healthy‑volunteer testing before use in pregnant patients.[3][4]\n\nIn an international early‑phase pilot trial in *Nature Medicine*:[1][3][4]\n\n- 16 women with severe early preeclampsia received the treatment  \n- Each session lowered circulating sFlt‑1 by ~17%[3][4]  \n- Blood pressure fell modestly but meaningfully[3][4]  \n- Disease progression appeared slower[1][2]  \n\nClinically, some pregnancies were prolonged, allowing time for:\n\n- Corticosteroids for fetal lung maturation  \n- Preparation for preterm delivery  \n\nOn average, treated women remained pregnant about 10 more days—over twice the duration seen in comparable untreated pregnancies.[4]\n\nShort‑term safety findings:[1][4]\n\n- No major device‑related complications  \n- Fetal growth remained appropriate during treatment  \n\nHowever, the study was:\n\n- Small (16 patients)  \n- Uncontrolled and not powered for definitive outcomes[1][2][4]  \n\n**Key point:** This device is the first therapy to directly remove a key pathogenic protein (sFlt‑1) in preeclampsia, but evidence comes from a small early‑stage cohort and needs confirmation in larger, controlled trials.[1][3][4]\n\n---\n\n## Implications, Limitations, and Future Directions in Preeclampsia Care\n\nA treatment that lowers sFlt‑1 could move care from purely symptom‑based management to **mechanism‑based intervention**, potentially:\n\n- Protecting maternal organs  \n- Safely prolonging pregnancy in selected patients[4][6]  \n\nThis blood‑filter strategy aligns with broader efforts to:[5]\n\n- Rebalance angiogenic factors (sFlt‑1 and placental growth factor)  \n- Improve placental blood flow  \n- Support endothelial health  \n\nDespite promise, current data are limited. The *Nature Medicine* trial:[2][3][4]\n\n- Included only 16 women—insufficient to detect rare side effects  \n- Was early phase and exploratory  \n- Required specialized equipment and expertise  \n- Left key questions: ideal candidates, treatment frequency, and integration with standard care  \n\n**Key takeaway:** The blood‑filter remains a research tool, not a routine therapy. Current management still relies on guideline‑based blood pressure control, close monitoring, and timely delivery.[6]\n\nBecause preeclampsia affects people in all regions and populations,[3][6] future therapies must be evaluated for:\n\n- Cost and scalability  \n- Use in low‑ and middle‑income settings  \n- Training needs and infrastructure demands[3][6]  \n\nAreas to watch:[5][6]\n\n- Larger randomized trials of sFlt‑1–targeted apheresis  \n- Expanded use of biomarkers (e.g., sFlt‑1\u002Fplacental growth factor ratios) for risk stratification  \n- Multidisciplinary care models that pair emerging treatments with counseling and long‑term cardiovascular follow‑up after preeclampsia  \n\n**Medical disclaimer:** This article is informational only and does not replace personalized medical advice. Preeclampsia management and any research participation must be guided by an obstetric or maternal–fetal medicine specialist.\n\n---\n\n## Conclusion: A Promising Step, Not Yet a New Standard\n\nPreeclampsia remains a dangerous, common pregnancy complication, and delivery is still the only definitive cure.[6] Early data show that targeted removal of sFlt‑1 via a blood‑filtering device can lower sFlt‑1, modestly reduce blood pressure, and sometimes extend pregnancy safely.[1][3][4]\n\nThese results are encouraging but preliminary. Larger, rigorous trials are essential before this therapy can be offered beyond research settings.[1][2][4]\n\nClinicians, researchers, and at‑risk parents should monitor upcoming trial results, consider enrollment in appropriate studies, and discuss evolving options for severe early preeclampsia with obstetric specialists to identify the safest, evidence‑based approach for each situation.","\u003Ch2>Understanding Preeclampsia and the Need for Better Treatments\u003C\u002Fh2>\n\u003Cp>Preeclampsia is a pregnancy‑specific disorder marked by new‑onset high blood pressure and organ dysfunction after 20 weeks of gestation in someone previously normotensive.\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa> It is a leading hypertensive complication of pregnancy and a major global cause of maternal and fetal illness and death.\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Affects ~3–8% of pregnancies worldwide\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Linked to >50,000 maternal and 500,000 fetal deaths annually\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cstrong>Key point:\u003C\u002Fstrong> Preeclampsia is common, dangerous, and the only curative therapy remains delivery.\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Main risk factors include:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Previous preeclampsia\u003C\u002Fli>\n\u003Cli>Chronic kidney disease\u003C\u002Fli>\n\u003Cli>Diabetes\u003C\u002Fli>\n\u003Cli>Obesity\u003C\u002Fli>\n\u003Cli>Advanced maternal age\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>These guide closer surveillance and prevention but cannot reliably stop severe disease.\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Current standard care focuses on:\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Controlling blood pressure with antihypertensives\u003C\u002Fli>\n\u003Cli>Monitoring kidney, liver, and neurological function\u003C\u002Fli>\n\u003Cli>Tracking fetal growth and placental health\u003C\u002Fli>\n\u003Cli>Planning safest timing and mode of delivery\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Because the placenta is central to the disease, removing it by delivery—induction or cesarean—is the only definitive cure.\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>The greatest challenge is \u003Cstrong>severe early preeclampsia\u003C\u002Fstrong> (before 34 weeks), when clinicians must balance:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Maternal safety and risk of organ failure\u003C\u002Fli>\n\u003Cli>Harm from very preterm birth, where every added day in utero can improve neonatal outcome\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Even a short, safe prolongation of pregnancy can be clinically meaningful.\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Key takeaway:\u003C\u002Fstrong> Early severe preeclampsia forces a trade‑off between maternal protection and extreme prematurity, creating a window where innovative therapies could have major impact.\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Chr>\n\u003Ch2>How the Blood-Filter Treatment Works and What the Trial Showed\u003C\u002Fh2>\n\u003Cp>A key driver of preeclampsia appears to be soluble Flt‑1 (sFlt‑1), a placental protein that can reach about five times normal levels.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Excess sFlt‑1:\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Damages blood vessel function\u003C\u002Fli>\n\u003Cli>Promotes hypertension\u003C\u002Fli>\n\u003Cli>Causes kidney injury and proteinuria\u003C\u002Fli>\n\u003Cli>Contributes to liver and brain complications and poor fetal growth\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>To target this, researchers:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Engineered an antibody that selectively binds sFlt‑1\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Embedded it in an extracorporeal blood‑filtering device that removes sFlt‑1 while sparing other blood components—similar in concept to \u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FKidney_dialysis\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">dialysis\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>The device underwent animal and healthy‑volunteer testing before use in pregnant patients.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>In an international early‑phase pilot trial in \u003Cem>Nature Medicine\u003C\u002Fem>:\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>16 women with severe early preeclampsia received the treatment\u003C\u002Fli>\n\u003Cli>Each session lowered circulating sFlt‑1 by ~17%\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Blood pressure fell modestly but meaningfully\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Disease progression appeared slower\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Clinically, some pregnancies were prolonged, allowing time for:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Corticosteroids for fetal lung maturation\u003C\u002Fli>\n\u003Cli>Preparation for preterm delivery\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>On average, treated women remained pregnant about 10 more days—over twice the duration seen in comparable untreated pregnancies.\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Short‑term safety findings:\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>No major device‑related complications\u003C\u002Fli>\n\u003Cli>Fetal growth remained appropriate during treatment\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>However, the study was:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Small (16 patients)\u003C\u002Fli>\n\u003Cli>Uncontrolled and not powered for definitive outcomes\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cstrong>Key point:\u003C\u002Fstrong> This device is the first therapy to directly remove a key pathogenic protein (sFlt‑1) in preeclampsia, but evidence comes from a small early‑stage cohort and needs confirmation in larger, controlled trials.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Chr>\n\u003Ch2>Implications, Limitations, and Future Directions in Preeclampsia Care\u003C\u002Fh2>\n\u003Cp>A treatment that lowers sFlt‑1 could move care from purely symptom‑based management to \u003Cstrong>mechanism‑based intervention\u003C\u002Fstrong>, potentially:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Protecting maternal organs\u003C\u002Fli>\n\u003Cli>Safely prolonging pregnancy in selected patients\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>This blood‑filter strategy aligns with broader efforts to:\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Rebalance angiogenic factors (sFlt‑1 and placental growth factor)\u003C\u002Fli>\n\u003Cli>Improve placental blood flow\u003C\u002Fli>\n\u003Cli>Support endothelial health\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Despite promise, current data are limited. The \u003Cem>Nature Medicine\u003C\u002Fem> trial:\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Included only 16 women—insufficient to detect rare side effects\u003C\u002Fli>\n\u003Cli>Was early phase and exploratory\u003C\u002Fli>\n\u003Cli>Required specialized equipment and expertise\u003C\u002Fli>\n\u003Cli>Left key questions: ideal candidates, treatment frequency, and integration with standard care\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cstrong>Key takeaway:\u003C\u002Fstrong> The blood‑filter remains a research tool, not a routine therapy. Current management still relies on guideline‑based blood pressure control, close monitoring, and timely delivery.\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Because preeclampsia affects people in all regions and populations,\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa> future therapies must be evaluated for:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Cost and scalability\u003C\u002Fli>\n\u003Cli>Use in low‑ and middle‑income settings\u003C\u002Fli>\n\u003Cli>Training needs and infrastructure demands\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Areas to watch:\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Larger randomized trials of sFlt‑1–targeted apheresis\u003C\u002Fli>\n\u003Cli>Expanded use of biomarkers (e.g., sFlt‑1\u002Fplacental growth factor ratios) for risk stratification\u003C\u002Fli>\n\u003Cli>Multidisciplinary care models that pair emerging treatments with counseling and long‑term cardiovascular follow‑up after preeclampsia\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cstrong>Medical disclaimer:\u003C\u002Fstrong> This article is informational only and does not replace personalized medical advice. Preeclampsia management and any research participation must be guided by an obstetric or maternal–fetal medicine specialist.\u003C\u002Fp>\n\u003Chr>\n\u003Ch2>Conclusion: A Promising Step, Not Yet a New Standard\u003C\u002Fh2>\n\u003Cp>Preeclampsia remains a dangerous, common pregnancy complication, and delivery is still the only definitive cure.\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa> Early data show that targeted removal of sFlt‑1 via a blood‑filtering device can lower sFlt‑1, modestly reduce blood pressure, and sometimes extend pregnancy safely.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>These results are encouraging but preliminary. Larger, rigorous trials are essential before this therapy can be offered beyond research settings.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Clinicians, researchers, and at‑risk parents should monitor upcoming trial results, consider enrollment in appropriate studies, and discuss evolving options for severe early preeclampsia with obstetric specialists to identify the safest, evidence‑based approach for each situation.\u003C\u002Fp>\n","Understanding Preeclampsia and the Need for Better Treatments\n\nPreeclampsia is a pregnancy‑specific disorder marked by new‑onset high blood pressure and organ dysfunction after 20 weeks of gestation i...","trend-radar",[],821,4,"2026-04-29T01:45:20.106Z",[17,22,26,30,34,38,42],{"title":18,"url":19,"summary":20,"type":21},"A blood‑filtering treatment can reduce high blood pressure and safely lower levels of a protein linked to very early and serious preeclampsia, according to a pilot study in Nature Medicine.","https:\u002F\u002Fwww.facebook.com\u002FNaturePortfolioJournals\u002Fposts\u002Fa-bloodfiltering-treatment-can-reduce-high-blood-pressure-and-safely-lower-level\u002F1449446817211580\u002F","A blood‑filtering treatment can reduce high blood pressure and safely lower levels of a protein linked to very early and serious preeclampsia, according to a pilot study in Nature Medicine. \n\nAlthough...","kb",{"title":23,"url":24,"summary":25,"type":21},"A blood‑filtering treatment can reduce high blood pressure and safely lower levels of a protein linked to very early and serious preeclampsia, according to a pilot study in Nature Medicine. Although larger studies are needed, the findings suggest that this treatment could help slow the progression of preeclampsia during pregnancy and reduce the risk of preterm delivery.","https:\u002F\u002Fwww.threads.com\u002F@nature.portfolio\u002Fpost\u002FDXpcUAYmEsU\u002Fa-blood-filtering-treatment-can-reduce-high-blood-pressure-and-safely-lower","A blood‑filtering treatment can reduce high blood pressure and safely lower levels of a protein linked to very early and serious preeclampsia, according to a pilot study in Nature Medicine. Although l...",{"title":27,"url":28,"summary":29,"type":21},"This dangerous pregnancy complication is common. A new treatment might help","https:\u002F\u002Fwww.sciencenews.org\u002Farticle\u002Fpreeclampsia-treatment-pregnancy-blood","Filtering a protein out of a pregnant person’s blood may help ease a dangerous complication.\n\nIn a study of 16 women with early preeclampsia, pulling a particular protein from their blood slightly low...",{"title":31,"url":32,"summary":33,"type":21},"New blood filtering treatment safely extends pregnancy in severe preeclampsia","https:\u002F\u002Fwww.news-medical.net\u002Fnews\u002F20260427\u002FNew-blood-filtering-treatment-safely-extends-pregnancy-in-severe-preeclampsia.aspx","Cedars-Sinai Health Sciences University investigators have developed and successfully tested a new treatment for pregnant women with severe early preeclampsia, a leading cause of premature birth as we...",{"title":35,"url":36,"summary":37,"type":21},"New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations","https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10418829\u002F","# New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations\n\n[Agata Sakowicz](https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F?term=%22Sakowicz%20A%22[Author])\n\n### Agata Sakowicz\n\n1...",{"title":39,"url":40,"summary":41,"type":21},"The Management of Preeclampsia: A Comprehensive Review of Current Practices and Future Directions","https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10832549\u002F","Preeclampsia (PE) is a disease in pregnancy that is characterized by new-onset hypertension end-organ dysfunction, often occurring after 20 weeks of gestation. Risk factors include a prior history of ...",{"title":43,"url":44,"summary":45,"type":21},"GUIDELINES Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care \n\nSecond update 2022\n\nSibylle Kietaibl, Aamer Ahmed, Arash Afshari, Pierre Albaladejo, Cesar Aldecoa, Giedrius Barauskas, Edoardo De Robertis, David Faraoni, Daniela C. Filipescu, Dietmar Fries, Anne Godier, Thorsten Haas, Matthias Jacob, Marcus D. Lanc \u0013e, Juan V. Llau, Jens Meier, Zsolt Molnar, Lidia Mora, Niels Rahe-Meyer, Charles M. Samama, Ecaterina Scarlatescu, Christoph Schlimp, Anne J. Wikkelsø and Kai Zacharowski","https:\u002F\u002Fdownload.s21i.co99.net\u002F32111785\u002F0\u002F1\u002FABUIABA9GAAgktCbtgYokqqRhgE.pdf?f=2022%20ESAIC%E6%8C%87%E5%8D%97%EF%BC%9A%E4%B8%A5%E9%87%8D%E5%9B%B4%E6%89%8B%E6%9C%AF%E6%9C%9F%E5%87%BA%E8%A1%80%E7%9A%84%E7%AE%A1%E7%90%86%EF%BC%88%E7%AC%AC2%E6%AC%A1%E6%9B%B4%E6%96%B0%EF%BC%89.pdf&v=1724311571","Background\nManagement of peri-operative bleeding is complex and involves multiple assessment tools and strategies to ensure optimal patient care with the goal of reducing morbidity and mortality. Thes...",{"totalSources":47},7,{"generationDuration":49,"kbQueriesCount":47,"confidenceScore":50,"sourcesCount":47},170553,100,{"metaTitle":52,"metaDescription":53},"Blood-Filter Treatment for Preeclampsia: Extend Pregnancy","Blood-filter treatment lowers BP in early preeclampsia. A trial tests if filtering harmful factors can safely prolong pregnancy—read the potential to cut preter","en","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1565562591245-00f5d7c4bf57?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxibG9vZCUyMGZpbHRlciUyMHRyZWF0bWVudCUyMGxvd2Vyc3xlbnwxfDB8fHwxNzc3NDI2NjExfDA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60",{"photographerName":57,"photographerUrl":58,"unsplashUrl":59},"Chaozzy Lin","https:\u002F\u002Funsplash.com\u002F@chaozzy?utm_source=coreprose&utm_medium=referral","https:\u002F\u002Funsplash.com\u002Fphotos\u002Fred-powder-in-three-clear-drinking-glasses-4DAzYHVEqd8?utm_source=coreprose&utm_medium=referral",true,"blood-filter-treatment-that-lowers-blood-pressure-in-preeclampsia-trial",{"key":63,"name":64,"nameEn":65},"sante","Santé & Médecine","Health & Medicine",[67,69,71,73],{"text":68},"Preeclampsia affects 3–8% of pregnancies worldwide and is linked to over 50,000 maternal and 500,000 fetal deaths annually.",{"text":70},"Delivery is the only definitive cure for preeclampsia; current care focuses on blood pressure control, organ monitoring, and timing of delivery.",{"text":72},"An antibody‑based extracorporeal blood‑filter reduced circulating sFlt‑1 by ~17% per session and, in a 16‑patient pilot, prolonged pregnancy by about 10 days on average.",{"text":74},"The device showed no major device‑related complications in the small trial, but evidence is limited by the uncontrolled, early‑phase design and small sample size.",[76,79,82],{"question":77,"answer":78},"How does the blood‑filter treatment work and what did the trial demonstrate?","The device directly removes the pathogenic protein sFlt‑1 from maternal circulation using an antibody embedded in an extracorporeal filter, sparing other blood components. In a phase‑1 pilot of 16 women with severe early preeclampsia, each session lowered circulating sFlt‑1 by approximately 17%, produced modest but clinically meaningful reductions in blood pressure, and was associated with an average pregnancy prolongation of about 10 days compared with expected courses; no major device‑related complications were reported in this small cohort.",{"question":80,"answer":81},"Who might be a candidate for this sFlt‑1–targeted apheresis in the future?","Candidates would be pregnant people with severe early preeclampsia (before 34 weeks) where the clinical team judges that safely prolonging pregnancy for fetal benefit is possible and maternal risk remains manageable. Selection will likely require elevated sFlt‑1 or abnormal sFlt‑1\u002FPlGF biomarker profiles, multidisciplinary evaluation by maternal–fetal medicine specialists, and access to the specialized equipment and monitoring needed for extracorporeal therapy; definitive eligibility criteria must await larger randomized trials.",{"question":83,"answer":84},"What are the main limitations of the current evidence and next research steps?","The primary limitations are the small, uncontrolled nature of the initial study (16 patients), which cannot detect rare harms or definitively establish efficacy, and the logistical challenges of specialized apheresis equipment and training. Next steps are larger, randomized controlled trials to confirm safety and efficacy, determine optimal treatment frequency and timing, identify ideal candidates via biomarkers, and assess cost, scalability, and applicability in low‑ and middle‑income settings.",[86,94,100,105,111,115,120,126,131,137,143,147,153,158,163],{"id":87,"name":88,"type":89,"confidence":90,"wikipediaUrl":91,"slug":92,"mentionCount":93},"69f162e88e996ffbd50f4374","endothelial dysfunction \u002F vascular damage","concept",0.93,null,"69f162e88e996ffbd50f4374-endothelial-dysfunction-vascular-damage",1,{"id":95,"name":96,"type":89,"confidence":97,"wikipediaUrl":98,"slug":99,"mentionCount":93},"69f162e78e996ffbd50f4372","dialysis",0.85,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FKidney_dialysis","69f162e78e996ffbd50f4372-dialysis",{"id":101,"name":102,"type":89,"confidence":103,"wikipediaUrl":91,"slug":104,"mentionCount":93},"69f162e78e996ffbd50f4370","sFlt-1\u002Fplacental growth factor ratio",0.89,"69f162e78e996ffbd50f4370-sflt-1-placental-growth-factor-ratio",{"id":106,"name":107,"type":108,"confidence":109,"wikipediaUrl":91,"slug":110,"mentionCount":93},"69f162e78e996ffbd50f436e","corticosteroids","drug",0.9,"69f162e78e996ffbd50f436e-corticosteroids",{"id":112,"name":113,"type":108,"confidence":109,"wikipediaUrl":91,"slug":114,"mentionCount":93},"69f162e78e996ffbd50f436d","antihypertensives","69f162e78e996ffbd50f436d-antihypertensives",{"id":116,"name":117,"type":108,"confidence":118,"wikipediaUrl":91,"slug":119,"mentionCount":93},"69f162e68e996ffbd50f436a","antibody that selectively binds sFlt-1",0.88,"69f162e68e996ffbd50f436a-antibody-that-selectively-binds-sflt-1",{"id":121,"name":122,"type":123,"confidence":124,"wikipediaUrl":91,"slug":125,"mentionCount":93},"69f162e68e996ffbd50f4367","severe early preeclampsia","medical_condition",0.96,"69f162e68e996ffbd50f4367-severe-early-preeclampsia",{"id":127,"name":128,"type":123,"confidence":129,"wikipediaUrl":91,"slug":130,"mentionCount":93},"69f162e58e996ffbd50f4366","Preeclampsia",0.99,"69f162e58e996ffbd50f4366-preeclampsia",{"id":132,"name":133,"type":134,"confidence":135,"wikipediaUrl":91,"slug":136,"mentionCount":93},"69f162e88e996ffbd50f4373","early-phase pilot trial (international)","medical_study",0.94,"69f162e88e996ffbd50f4373-early-phase-pilot-trial-international",{"id":138,"name":139,"type":140,"confidence":141,"wikipediaUrl":91,"slug":142,"mentionCount":93},"69f162e78e996ffbd50f4371","placenta","other",0.95,"69f162e78e996ffbd50f4371-placenta",{"id":144,"name":145,"type":140,"confidence":109,"wikipediaUrl":91,"slug":146,"mentionCount":93},"69f162e68e996ffbd50f436c","16 women","69f162e68e996ffbd50f436c-16-women",{"id":148,"name":149,"type":150,"confidence":151,"wikipediaUrl":91,"slug":152,"mentionCount":93},"69f162e68e996ffbd50f4369","blood-filtering device","product",0.92,"69f162e68e996ffbd50f4369-blood-filtering-device",{"id":154,"name":155,"type":156,"confidence":135,"wikipediaUrl":91,"slug":157,"mentionCount":93},"69f162e68e996ffbd50f436b","Nature Medicine trial","scholarly_article","69f162e68e996ffbd50f436b-nature-medicine-trial",{"id":159,"name":160,"type":161,"confidence":109,"wikipediaUrl":91,"slug":162,"mentionCount":93},"69f162e78e996ffbd50f436f","placental growth factor","substance","69f162e78e996ffbd50f436f-placental-growth-factor",{"id":164,"name":165,"type":161,"confidence":166,"wikipediaUrl":91,"slug":167,"mentionCount":93},"69f162e68e996ffbd50f4368","soluble Flt-1",0.98,"69f162e68e996ffbd50f4368-soluble-flt-1",[169,176,183,190],{"id":170,"title":171,"slug":172,"excerpt":173,"category":11,"featuredImage":174,"publishedAt":175},"69e36b5835e5aa429da4bde4","How Zeaxanthin Supercharges CD8+ T Cells to Make Cancer Immunotherapy More Effective","how-zeaxanthin-supercharges-cd8-t-cells-to-make-cancer-immunotherapy-more-effective","Zeaxanthin is a yellow‑orange carotenoid found in corn, spinach, kale, and orange peppers. Best known for eye health and macular protection, it filters blue light and acts as an antioxidant.[1][2]...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1666402667406-df3723f1b777?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHx6ZWF4YW50aGluJTIwZW5oYW5jZXMlMjBjZWxscyUyMGJvb3N0c3xlbnwxfDB8fHwxNzc2NTExODMxfDA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-18T11:41:20.255Z",{"id":177,"title":178,"slug":179,"excerpt":180,"category":11,"featuredImage":181,"publishedAt":182},"69df07d1461a4d3bb7139375","How Zeaxanthin Supercharges T Cells and Could Transform Cancer Immunotherapy","how-zeaxanthin-supercharges-t-cells-and-could-transform-cancer-immunotherapy","From eye vitamin to immune ally: what zeaxanthin is and why it matters\n\nZeaxanthin is a yellow‑orange carotenoid in plants, especially leafy greens like spinach and kale, and yellow vegetables such as...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1666402667406-df3723f1b777?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHx6ZWF4YW50aGluJTIwbnV0cmllbnQlMjBzdHJlbmd0aGVucyUyMGNlbGxzfGVufDF8MHx8fDE3NzYyMjQyMDl8MA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-15T03:44:01.558Z",{"id":184,"title":185,"slug":186,"excerpt":187,"category":11,"featuredImage":188,"publishedAt":189},"69dd33271bfde9ce63ff8576","Gut Bacteria-Produced Sugars: The Hidden Trigger Behind ALS and Frontotemporal Dementia","gut-bacteria-produced-sugars-the-hidden-trigger-behind-als-and-frontotemporal-dementia","From Gut to Brain: How Bacterial Sugars Drive ALS and Frontotemporal Dementia  \n\nAmyotrophic lateral sclerosis (ALS) rapidly destroys motor neurons, progressing from weakness to paralysis and loss of...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1684844027899-63f6d470b9f3?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxndXQlMjBiYWN0ZXJpYSUyMHByb2R1Y2VkJTIwc3VnYXJzfGVufDF8MHx8fDE3NzYxMDQyMzF8MA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-13T18:24:39.126Z",{"id":191,"title":192,"slug":193,"excerpt":194,"category":11,"featuredImage":195,"publishedAt":196},"69d48127fc9a83011893c2c3","How Digital Heart Twins Guided Successful VT Ablation in 10 Patients","how-digital-heart-twins-guided-successful-vt-ablation-in-10-patients","From Ventricular Tachycardia to Digital Heart Twins: Why This Trial Matters\n\nVentricular tachycardia (VT) is a rapid rhythm from the heart’s lower chambers that can degenerate into ventricular fibrill...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1739185253617-4fdc1cd3d62a?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxkaWdpdGFsJTIwaGVhcnQlMjB0d2lucyUyMGd1aWRlZHxlbnwxfDB8fHwxNzc1NTM0Mzc1fDA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-07T04:07:18.077Z",["Island",198],{"key":199,"params":200,"result":202},"ArticleBody_plCtovgxSNlHCFz1qEAa0xy0WCNMVP1M3ipG9wzmxA",{"props":201},"{\"articleId\":\"69f160b33a60b2a09f4b96f6\"}",{"head":203},{}]